These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8648918)
1. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Abramowicz D; Norman DJ; Vereerstraeten P; Goldman M; De Pauw L; Vanherweghem JL; Kinnaert P; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Wu SC; Haverty TP Kidney Int; 1996 Mar; 49(3):768-72. PubMed ID: 8648918 [TBL] [Abstract][Full Text] [Related]
2. OKT3 for primary therapy of the first rejection episode in kidney transplants. Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875 [TBL] [Abstract][Full Text] [Related]
3. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Abramowicz D; Norman DJ; Goldman M; De Pauw L; Kinnaert P; Kahana L; Thistlethwaite JR; Shield CF; Monaco AP; Vanherweghem JL Transplant Proc; 1995 Feb; 27(1):852-3. PubMed ID: 7879204 [No Abstract] [Full Text] [Related]
4. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Opelz G Transplantation; 1995 Dec; 60(11):1220-4. PubMed ID: 8525514 [TBL] [Abstract][Full Text] [Related]
6. The role of cold ischemia in a provincial organ-sharing program in the cyclosporine era. Jordan ML; Aprile MA; Cardella CJ Transplantation; 1990 Feb; 49(2):367-73. PubMed ID: 2305466 [TBL] [Abstract][Full Text] [Related]
7. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Benfield MR; Tejani A; Harmon WE; McDonald R; Stablein DM; McIntosh M; Rose S; Pediatr Transplant; 2005 Jun; 9(3):282-92. PubMed ID: 15910382 [TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224 [TBL] [Abstract][Full Text] [Related]
9. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187 [TBL] [Abstract][Full Text] [Related]
10. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Farges O; Ericzon BG; Bresson-Hadni S; Lynch SV; Höckerstedt K; Houssin D; Galmarini D; Faure JL; Baldauf C; Bismuth H Transplantation; 1994 Oct; 58(8):891-8. PubMed ID: 7940732 [TBL] [Abstract][Full Text] [Related]
11. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation. Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356 [TBL] [Abstract][Full Text] [Related]
12. Effect of OKT3 in steroid-resistant renal transplant rejection. Petrie JJ; Rigby RJ; Hawley CM; Suranyi MG; Whitby M; Wall D; Hardie IR Transplantation; 1995 Feb; 59(3):347-52. PubMed ID: 7871563 [TBL] [Abstract][Full Text] [Related]
13. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115 [TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063 [TBL] [Abstract][Full Text] [Related]
16. Long-term results of OKT3-treated renal transplant recipients. Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689 [No Abstract] [Full Text] [Related]
17. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506 [TBL] [Abstract][Full Text] [Related]
19. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873 [TBL] [Abstract][Full Text] [Related]
20. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens. Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684 [No Abstract] [Full Text] [Related] [Next] [New Search]